IBDEI0I9 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8215,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8215,1,3,0)
;;=3^Obesity,Unspec
;;^UTILITY(U,$J,358.3,8215,1,4,0)
;;=4^E66.9
;;^UTILITY(U,$J,358.3,8215,2)
;;=^5002832
;;^UTILITY(U,$J,358.3,8216,0)
;;=E74.39^^39^394^16
;;^UTILITY(U,$J,358.3,8216,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8216,1,3,0)
;;=3^Intestinal Carbohydrate Absorption Disorder NEC
;;^UTILITY(U,$J,358.3,8216,1,4,0)
;;=4^E74.39
;;^UTILITY(U,$J,358.3,8216,2)
;;=^5002928
;;^UTILITY(U,$J,358.3,8217,0)
;;=E83.30^^39^394^28
;;^UTILITY(U,$J,358.3,8217,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8217,1,3,0)
;;=3^Phosphorus Metabolism Disorder,Unspec
;;^UTILITY(U,$J,358.3,8217,1,4,0)
;;=4^E83.30
;;^UTILITY(U,$J,358.3,8217,2)
;;=^5002997
;;^UTILITY(U,$J,358.3,8218,0)
;;=E83.51^^39^394^9
;;^UTILITY(U,$J,358.3,8218,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8218,1,3,0)
;;=3^Hypocalcemia
;;^UTILITY(U,$J,358.3,8218,1,4,0)
;;=4^E83.51
;;^UTILITY(U,$J,358.3,8218,2)
;;=^60542
;;^UTILITY(U,$J,358.3,8219,0)
;;=E83.52^^39^394^7
;;^UTILITY(U,$J,358.3,8219,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8219,1,3,0)
;;=3^Hypercalcemia
;;^UTILITY(U,$J,358.3,8219,1,4,0)
;;=4^E83.52
;;^UTILITY(U,$J,358.3,8219,2)
;;=^59932
;;^UTILITY(U,$J,358.3,8220,0)
;;=E87.5^^39^394^8
;;^UTILITY(U,$J,358.3,8220,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8220,1,3,0)
;;=3^Hyperkalemia
;;^UTILITY(U,$J,358.3,8220,1,4,0)
;;=4^E87.5
;;^UTILITY(U,$J,358.3,8220,2)
;;=^60041
;;^UTILITY(U,$J,358.3,8221,0)
;;=E89.2^^39^394^30
;;^UTILITY(U,$J,358.3,8221,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8221,1,3,0)
;;=3^PostProcedural Hypoparathyroidism
;;^UTILITY(U,$J,358.3,8221,1,4,0)
;;=4^E89.2
;;^UTILITY(U,$J,358.3,8221,2)
;;=^5003037
;;^UTILITY(U,$J,358.3,8222,0)
;;=E89.6^^39^394^29
;;^UTILITY(U,$J,358.3,8222,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8222,1,3,0)
;;=3^PostProcedural Adrenocortical Hypofunction
;;^UTILITY(U,$J,358.3,8222,1,4,0)
;;=4^E89.6
;;^UTILITY(U,$J,358.3,8222,2)
;;=^5003042
;;^UTILITY(U,$J,358.3,8223,0)
;;=L68.0^^39^394^6
;;^UTILITY(U,$J,358.3,8223,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8223,1,3,0)
;;=3^Hirsutism
;;^UTILITY(U,$J,358.3,8223,1,4,0)
;;=4^L68.0
;;^UTILITY(U,$J,358.3,8223,2)
;;=^5009262
;;^UTILITY(U,$J,358.3,8224,0)
;;=M80.00XA^^39^394^2
;;^UTILITY(U,$J,358.3,8224,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8224,1,3,0)
;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
;;^UTILITY(U,$J,358.3,8224,1,4,0)
;;=4^M80.00XA
;;^UTILITY(U,$J,358.3,8224,2)
;;=^5013363
;;^UTILITY(U,$J,358.3,8225,0)
;;=M81.0^^39^394^3
;;^UTILITY(U,$J,358.3,8225,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8225,1,3,0)
;;=3^Age-Related Osteoporosis w/o Fx
;;^UTILITY(U,$J,358.3,8225,1,4,0)
;;=4^M81.0
;;^UTILITY(U,$J,358.3,8225,2)
;;=^5013555
;;^UTILITY(U,$J,358.3,8226,0)
;;=M85.80^^39^394^26
;;^UTILITY(U,$J,358.3,8226,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8226,1,3,0)
;;=3^Osteopenia,Unspec Site
;;^UTILITY(U,$J,358.3,8226,1,4,0)
;;=4^M85.80
;;^UTILITY(U,$J,358.3,8226,2)
;;=^5014473
;;^UTILITY(U,$J,358.3,8227,0)
;;=N62.^^39^394^5
;;^UTILITY(U,$J,358.3,8227,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8227,1,3,0)
;;=3^Gynecomastia
;;^UTILITY(U,$J,358.3,8227,1,4,0)
;;=4^N62.
;;^UTILITY(U,$J,358.3,8227,2)
;;=^5015790
;;^UTILITY(U,$J,358.3,8228,0)
;;=E66.3^^39^394^27
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0I9 3793 printed Apr 09, 2024@21:57:50 Page 2
IBDEI0I9 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8215,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,8215,1,3,0)
+4 ;;=3^Obesity,Unspec
+5 ;;^UTILITY(U,$J,358.3,8215,1,4,0)
+6 ;;=4^E66.9
+7 ;;^UTILITY(U,$J,358.3,8215,2)
+8 ;;=^5002832
+9 ;;^UTILITY(U,$J,358.3,8216,0)
+10 ;;=E74.39^^39^394^16
+11 ;;^UTILITY(U,$J,358.3,8216,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,8216,1,3,0)
+14 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
+15 ;;^UTILITY(U,$J,358.3,8216,1,4,0)
+16 ;;=4^E74.39
+17 ;;^UTILITY(U,$J,358.3,8216,2)
+18 ;;=^5002928
+19 ;;^UTILITY(U,$J,358.3,8217,0)
+20 ;;=E83.30^^39^394^28
+21 ;;^UTILITY(U,$J,358.3,8217,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,8217,1,3,0)
+24 ;;=3^Phosphorus Metabolism Disorder,Unspec
+25 ;;^UTILITY(U,$J,358.3,8217,1,4,0)
+26 ;;=4^E83.30
+27 ;;^UTILITY(U,$J,358.3,8217,2)
+28 ;;=^5002997
+29 ;;^UTILITY(U,$J,358.3,8218,0)
+30 ;;=E83.51^^39^394^9
+31 ;;^UTILITY(U,$J,358.3,8218,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,8218,1,3,0)
+34 ;;=3^Hypocalcemia
+35 ;;^UTILITY(U,$J,358.3,8218,1,4,0)
+36 ;;=4^E83.51
+37 ;;^UTILITY(U,$J,358.3,8218,2)
+38 ;;=^60542
+39 ;;^UTILITY(U,$J,358.3,8219,0)
+40 ;;=E83.52^^39^394^7
+41 ;;^UTILITY(U,$J,358.3,8219,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,8219,1,3,0)
+44 ;;=3^Hypercalcemia
+45 ;;^UTILITY(U,$J,358.3,8219,1,4,0)
+46 ;;=4^E83.52
+47 ;;^UTILITY(U,$J,358.3,8219,2)
+48 ;;=^59932
+49 ;;^UTILITY(U,$J,358.3,8220,0)
+50 ;;=E87.5^^39^394^8
+51 ;;^UTILITY(U,$J,358.3,8220,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,8220,1,3,0)
+54 ;;=3^Hyperkalemia
+55 ;;^UTILITY(U,$J,358.3,8220,1,4,0)
+56 ;;=4^E87.5
+57 ;;^UTILITY(U,$J,358.3,8220,2)
+58 ;;=^60041
+59 ;;^UTILITY(U,$J,358.3,8221,0)
+60 ;;=E89.2^^39^394^30
+61 ;;^UTILITY(U,$J,358.3,8221,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,8221,1,3,0)
+64 ;;=3^PostProcedural Hypoparathyroidism
+65 ;;^UTILITY(U,$J,358.3,8221,1,4,0)
+66 ;;=4^E89.2
+67 ;;^UTILITY(U,$J,358.3,8221,2)
+68 ;;=^5003037
+69 ;;^UTILITY(U,$J,358.3,8222,0)
+70 ;;=E89.6^^39^394^29
+71 ;;^UTILITY(U,$J,358.3,8222,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,8222,1,3,0)
+74 ;;=3^PostProcedural Adrenocortical Hypofunction
+75 ;;^UTILITY(U,$J,358.3,8222,1,4,0)
+76 ;;=4^E89.6
+77 ;;^UTILITY(U,$J,358.3,8222,2)
+78 ;;=^5003042
+79 ;;^UTILITY(U,$J,358.3,8223,0)
+80 ;;=L68.0^^39^394^6
+81 ;;^UTILITY(U,$J,358.3,8223,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,8223,1,3,0)
+84 ;;=3^Hirsutism
+85 ;;^UTILITY(U,$J,358.3,8223,1,4,0)
+86 ;;=4^L68.0
+87 ;;^UTILITY(U,$J,358.3,8223,2)
+88 ;;=^5009262
+89 ;;^UTILITY(U,$J,358.3,8224,0)
+90 ;;=M80.00XA^^39^394^2
+91 ;;^UTILITY(U,$J,358.3,8224,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,8224,1,3,0)
+94 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
+95 ;;^UTILITY(U,$J,358.3,8224,1,4,0)
+96 ;;=4^M80.00XA
+97 ;;^UTILITY(U,$J,358.3,8224,2)
+98 ;;=^5013363
+99 ;;^UTILITY(U,$J,358.3,8225,0)
+100 ;;=M81.0^^39^394^3
+101 ;;^UTILITY(U,$J,358.3,8225,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,8225,1,3,0)
+104 ;;=3^Age-Related Osteoporosis w/o Fx
+105 ;;^UTILITY(U,$J,358.3,8225,1,4,0)
+106 ;;=4^M81.0
+107 ;;^UTILITY(U,$J,358.3,8225,2)
+108 ;;=^5013555
+109 ;;^UTILITY(U,$J,358.3,8226,0)
+110 ;;=M85.80^^39^394^26
+111 ;;^UTILITY(U,$J,358.3,8226,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,8226,1,3,0)
+114 ;;=3^Osteopenia,Unspec Site
+115 ;;^UTILITY(U,$J,358.3,8226,1,4,0)
+116 ;;=4^M85.80
+117 ;;^UTILITY(U,$J,358.3,8226,2)
+118 ;;=^5014473
+119 ;;^UTILITY(U,$J,358.3,8227,0)
+120 ;;=N62.^^39^394^5
+121 ;;^UTILITY(U,$J,358.3,8227,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,8227,1,3,0)
+124 ;;=3^Gynecomastia
+125 ;;^UTILITY(U,$J,358.3,8227,1,4,0)
+126 ;;=4^N62.
+127 ;;^UTILITY(U,$J,358.3,8227,2)
+128 ;;=^5015790
+129 ;;^UTILITY(U,$J,358.3,8228,0)
+130 ;;=E66.3^^39^394^27
